MARTIN RUSSELL POLLAK, MD
Osteopathic Medicine at Brookline Ave, Boston, MA
License number
Massachusetts 74736
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
330 Brookline Ave, Boston, MA 02215
Phone
(617) 632-9880
Professional information
Chief Of Nephrology, Beth Israel Deaconess Medical Center, Boston
Position:
Professor of Medicine, Chief of Nephrology at Beth Israel Deaconess Medical Center, Harvard Medical School
Location:
Greater Boston Area
Industry:
Hospital & Health Care
Work:
Beth Israel Deaconess Medical Center, Harvard Medical School
since Feb 2010
-
Professor of Medicine, Chief of Nephrology
Brigham and Women's Hospital
1991 - 2010
-
faculty
columbia-presbyterian medical center
1988 - 1991
-
medical resident
Education:
New York University School of Medicine 1984 - 1988
M.D. Princeton University 1979 - 1983
A.B., mathematics
M.D. Princeton University 1979 - 1983
A.B., mathematics
Interests:
Biotechnology,
DNA sequencing,
human genetics,
Genetic basis of kidney disease
Martin Russell Pollak, Boston MA
Specialties:
Emergency Medicine, Internal Medicine, Nephrology, Medical Oncology
Work:
Beth Israel Deaconess Medical Center
185 Pilgrim Rd, Boston, MA 02215
185 Pilgrim Rd, Boston, MA 02215
Education:
New York University (1988)
Martin Russell Pollak, Boston MA
Specialties:
Nephrologist
Address:
185 Pilgrim Rd, Boston, MA 02215
330 Brookline Ave, Boston, MA 02215
330 Brookline Ave, Boston, MA 02215
Education:
New York University, School of Medicine - Doctor of Medicine*
Board certifications:
American Board of Internal Medicine Sub-certificate in Nephrology (Internal Medicine)*
Dr. Martin R Pollak - MD (Doctor of Medicine)
Hospitals:
185 Pilgrim Rd STE FARR8, Boston 02215
Brigham and Women's Hospital NEP
75 Francis St, Boston 02115
185 Pilgrim Rd STE FARR8, Boston 02215
Brigham and Women's Hospital NEP
75 Francis St, Boston 02115
Brigham and Women's Hospital NEP
75 Francis St, Boston 02115
185 Pilgrim Rd STE FARR8, Boston 02215
Brigham and Women's Hospital NEP
75 Francis St, Boston 02115
Education:
Medical Schools
New York University School Of Medicine
Graduated: 1988
New York University School Of Medicine
Graduated: 1988
Martin Pollak
Location:
Greater Boston Area
Industry:
Biotechnology
Methods Of Predicting Predisposition To Or Risk Of Kidney Disease
US Patent:
2013007, Mar 28, 2013
Filed:
Apr 18, 2011
Appl. No.:
13/642054
Inventors:
Giulio Genovese - Boston MA, US
David J. Friedman - Boston MA, US
Martin R. Pollak - Boston MA, US
David J. Friedman - Boston MA, US
Martin R. Pollak - Boston MA, US
International Classification:
C12Q 1/68
US Classification:
506 9, 435 611
Abstract:
Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with infection, e.g., by detecting at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with . The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and/or a deletion of N388 and Y389 to the subject.
Compositions And Methods For Treating Renal Disease
US Patent:
2012019, Aug 2, 2012
Filed:
Feb 24, 2012
Appl. No.:
13/404725
Inventors:
David J. Friedman - Boston MA, US
Martin R. Pollak - Boston MA, US
Martin R. Pollak - Boston MA, US
Assignee:
Beth Israel Deaconess Medical Center, Inc. - Boston MA
International Classification:
A61K 39/395, C12Q 1/68, A61P 3/06, A61P 13/12, A61P 9/00, C07K 16/18, G01N 33/566
US Classification:
4241391, 5303879, 435 611, 436501, 435 792
Abstract:
Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease (ESKD), and HIV-associated nephropathy (a distinct form of FSGS, also termed collapsing glomerulopathy). The compositions include the common variant of APOL1 and fragments thereof, as well as antibodies and fragments thereof that bind and neutralize pathogenic APOL1, nucleic acid molecules that encode the common variant of APOL1 and fragments thereof, and other compounds that bind and neutralize pathogenic APOL1. The methods of the invention include administering one or more of the compositions of the invention to a subject having or at risk of developing renal disease.